Johns Hopkins Uncovers Key Sex and Menopause Influences on Early Lyme Disease Presentation

A groundbreaking study from the Johns Hopkins Lyme Disease Research Center has revealed significant differences in how early Lyme disease manifests based on biological sex and menopausal status. Published on February 7, 2026, in Clinical and Experimental Medicine, the prospective cohort analysis highlights variations in symptoms, physical signs, serologic responses, and overall disease severity among 243 adult patients with physician-confirmed erythema migrans (EM) rash—the hallmark bull's-eye lesion of early Lyme disease caused by the spirochete bacterium Borrelia burgdorferi (Bb). This research underscores the role of sex hormones in modulating immune responses to Bb, potentially affecting timely diagnosis and treatment outcomes.

Lyme disease, the most common vector-borne illness in the United States, affects an estimated 476,000 people annually according to the Centers for Disease Control and Prevention (CDC). Transmitted primarily by blacklegged ticks (Ixodes scapularis) in the Northeast, Mid-Atlantic, and Upper Midwest regions, early symptoms often include the EM rash (appearing in 70-80% of cases), flu-like fatigue, fever, headache, and muscle aches. Untreated, it can progress to disseminated stages involving joints, heart, and nervous system.

Study Methodology: The SLICE Cohort's Rigorous Design

Conducted as part of the long-running Study of Lyme Disease Immunology and Clinical Events (SLICE)—initiated in 2008 by the Johns Hopkins team—this prospective study enrolled antibiotic-naïve adults aged 20-84 from the Mid-Atlantic U.S. with EM rashes ≥5 cm. Participants (125 males, 118 females: 79 pre-menopausal, 39 post-menopausal) underwent baseline assessments including symptoms (36-item questionnaire), physical exams (rash size, dissemination, lymphadenopathy), labs (CBC for neutrophil-lymphocyte ratio [NLR], CMP for liver function tests [LFTs]), and two-tier serology (ELISA followed by IgM/IgG Western blot per CDC criteria). Follow-up occurred ~3 weeks post-antibiotics. Disease severity was scored 0-6 based on rash >80 cm², >6 symptoms, dissemination, seropositivity, elevated LFTs, NLR >2.97. Analyses used adjusted logistic/ordinal models controlling for age, illness duration, steroids, thyroid disease.

Exclusions ensured purity: no prior Lyme, antibiotics, or comorbidities like autoimmunity. This design allowed precise dissection of acute-phase differences, free from confounding treatments.

Symptom Profiles: Subtle but Telling Variations by Sex

While total symptom counts were similar across groups, specific patterns emerged. Females reported higher rates of heart palpitations (11.9% vs. 4% males, p=0.023), vomiting (7.6% vs. <1%, p=0.007), and photophobia/light sensitivity (17% vs. 8.8%, p=0.057). Males experienced more sleep disruption (40% vs. 24.6%, p=0.010). Trends included female predominance in neck pain/nausea, male in irritability. No menopausal symptom differences were significant, though sore throat trended lower post-menopause (p=0.060).

These align with prior observations: women often report multisystem complaints, potentially delaying diagnosis as 'atypical.' For context, prior studies note men with larger EM rashes (~2 cm bigger), higher cardiac/neurologic PTLDS risk, women more arthritis PTLDS—though early disease data was sparse.

Clinicians should query sex-specific symptoms; overlooking them risks misattribution to anxiety or perimenopause in women.

Serologic Responses: Males Mount Stronger Antibody Production

Males showed higher two-tier seropositivity odds (OR=1.77 [1.03-3.04], p=0.039 vs. females), pronounced vs. pre-menopausal females (OR=2.93 [1.26-6.79], p=0.012), but not post-menopausal (OR=1.41, p=0.266). Pre-menopausal women had lower V1 positivity, slower V2 seroconversion.

This challenges assumptions: lower female seroreactivity (despite robust humoral immunity generally) suggests vigorous innate responses limiting spirochetemia/antigen load, reducing need for antibodies. Post-menopausal similarity to males implicates estrogen decline.

Disease Severity: Objective Markers Favor Male Prominence

Males scored higher on severity (OR=1.94 [1.20-3.15], p=0.028 vs. females; OR=2.26 [1.13-4.58], p=0.044 vs. pre-menopausal), driven by larger rashes, dissemination, LFT elevations, high NLR—inflammation proxy. Illness duration identical, ruling delay bias.

• Larger EM: >80 cm² more common in males.
• Dissemination (multiple lesions): Male skew.
• LFTs elevated: Indicating hepatic involvement.
• NLR >2.97: Systemic inflammation.

No physical exam differences beyond rash. Pre-menopausal protection evident; post-menopausal shift.

Photo by Logan Voss on Unsplash

The Menopause Factor: Hormonal Shifts Reshape Responses

Post-menopausal women (estrogen/progesterone drop) mirrored males: higher seropositivity, severity—vs. pre-menopausal divergence. Estrogen modulates immunity: pro-Th2 humoral, anti-inflammatory at high levels; protects via endothelial modulation, Bb phagocytosis enhancement. Progesterone anti-inflammatory. Menopause akin to 'male-like' state, aligning with autoimmunity surge (e.g., rheumatoid arthritis).

Dr. John Aucott notes: "Males and females are different... the male group was more similar to females who had undergone menopause." Next: hormone assays in SLICE to confirm.

Broader Context: Prior Evidence of Sex Disparities in Lyme

Reported cases skew male (56%), but underdiagnosis in females suspected—women face diagnostic odysseys, PTLDS (10-20%). Men: larger rashes, tick-noticing; women: disseminated arthritis PTLDS. Hormones key: estrogen boosts B-cells, but Bb exploits; progesterone curbs inflammation.

CDC data: Bimodal peaks (5-9, 55-59 years); males higher incidence. Yet women ~2x PTLDS risk, per MyLymeData.

Diagnostic and Treatment Implications for Clinicians

Pre-menopausal women: lower serology/severity may yield false negatives (STTT sensitivity ~40-50% early), prolonging diagnosis. Tailor: clinical judgment over labs alone; sex/menopause history. Antibiotics (doxycycline 10-21 days) effective early, but PTLDS risk tied to dissemination/inflammation—male/post-menopausal higher?

Actionable: Prompt EM biopsy/culture? Hormone-informed trials. For researchers, explore higher ed research jobs in infectious diseases at institutions like Johns Hopkins.

Johns Hopkins Lyme Center: Pioneering Patient-Centered Research

Established 2015, the center—led by Dr. Aucott—hosts SLICE (500+ enrolled), probing immunology, PTLDS (14% early-treated develop). Multidisciplinary: rheumatology, neurology, immunology. Funded by Cohen/Global Lyme Alliance/Bay Area foundations. Bridges gaps: why 10-20% PTLDS?

Opportunities abound for faculty positions in vector-borne research.

Future Directions: Hormones, PTLDS, and Personalized Medicine

Pending: SLICE hormone profiling, Bb load assays, PTLDS prediction. Broader: sex-disaggregated trials; vaccines (VLA15/VLS-01 target OspA). Climate/tick range expansion amplifies need—Northeast cases up 300% decade.

• Mechanisms: Estrogen-Bb interactions.
• Interventions: Hormone adjuncts?
• Equity: Female-focused diagnostics.

This advances precision medicine in infectious diseases. Explore career advice for Lyme researchers.

Photo by Pawel Czerwinski on Unsplash

Key Takeaways and Call to Action

Johns Hopkins illuminates sex/menopause modulation of early Lyme: males/post-menopausal severe/seropositive; pre-menopausal milder. Revolutionizes dx: beyond one-size-fits-all. Stay vigilant: tick checks, DEET/permethrin. For academics, higher-ed jobs in immunology await; rate your professors; pursue postdoc success.

Discuss in comments—your insights matter.